Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.
-
Industry
-
Biotechnology Research
-
Company size
-
51-200 employees
-
Headquarters
-
South San Francisco, California
-
Type
-
Privately Held
-
Founded
-
2018
-
Specialties
-
biotech, precision medicine, immunological diseases, neurological diseases, neurodegenerative diseases, neuroinflammatory diseases, autoimmune diseases, inflammatory diseases, human genetics, data science, Parkinson's disease, Crohn's disease, Ulcerative colitis, psoriasis, IBD, and ankylosing spondylitis